Session 1: 09:30 – 11:35

Nepal time

Speaker’s time

Chairs

Dr. Pradip Gyanwali, Prof. Dr. Bishnu Dutta Paudel

9:30-9:35

S.N.

Speakers

Title of talk

1.

Dr. Daniel Fowler, CMO, RAPA Therapeutics, USA

Naturally occurring Polyclonal T-cells for the treatment of neurological disorders ALS

9:35-10:05

22:50 -23:20 (EST)

2

Prof. Renato Cunha, National Leader Cell Therapy Program, Brazil

Developing CAR-T cell in low middle income countries: A learning from Brazil

10:05-10:35

23:20 – 23:50 (EST)

3

Dr. Eric Tran, Providence, Oregon

Neoantigen T-cell receptor therapy in solid cancer

10:35 -11:05

20:50 – 21:20 (PST)

4

Dr Jessica Fioravanti           Sr Scientist, Lyell, USA

iPSC derived cells to potentiate off-the-shelf ACT therapies

11:05-11:35

21:20 – 21:50 (PST)

Session 1: 11:50 – 13:15

Times

Chairs

Prof. Dr. Anjani Jha and Dr. Madan Kumar Piya

11:50-11:55

S.N.

Speakers

Title of talk

1

Dr. Bishesh Poudel, Civil Hospital, Nepal

Currents standards in the management of haematological malignancies in Nepal

11:55-12:10

2

Dr. Sudip Shrestha Nepal Cancer Hospital, Nepal

Current standards in the management of solid tumors in Nepal

12:10-12:25

3.

Prof. Luca Gattinoni Director, LIIT, Germany

Harnessing T-cell stemness for Adoptive T-Cell Therapy

12:25-13:15

Session 3: 14:00 – 

Times

Chairs

Prof. Luca Gattinoni, MD, and Prof. Dr. Aarati Shah, Dr RP Baral

14:00-14:05

S.N.

Speakers

Title of talk

1

Dr. Sanjivan Gautam, Director, AstraZeneca, USA 

Technological Advancement for Mitigation of CAR mediated side effects

14:05-14:35

2

Dr. Manakamana Khanal, Scientist, NCI, USA

Immunotoxin and CAR-T Cell Combo Therapy for Mesothelin Expressing Solid Cancer 

14:35-15:00

1

Dr. Ramila Shilpakar, NAMS, Nepal

Feasibility of CAR-T cell in Nepal

15:00 -15:15

4.

Dr Om Kurmi               Epidemiologist, UK.

Considerations for the Design of Early-Phase Clinical Trials of Cellular Products

15:15-15:35